The global medical community has reached a watershed moment in the battle against viral hepatitis. According to the latest estimates from the World Health Organization (WHO), the prevalence of chronic hepatitis B virus (HBV) infection among children under the age of five has plummeted to less than 1%. This achievement signifies the attainment of a critical Sustainable Development Goal (SDG) target, marking a monumental shift from the "pre-vaccine era," when childhood prevalence hovered around 5%.
While this milestone offers a beacon of hope, it is tempered by the looming shadow of the COVID-19 pandemic and deep-seated inequities in vaccine access. As the world marks World Hepatitis Day, the message from health authorities is clear: the success of the past two decades is fragile, and the path to a truly "hepatitis-free future" requires renewed,, and urgent commitment.
The Chronology of Progress: From the 1980s to the 2020 Milestone
The fight against hepatitis B has been a decades-long endeavor defined by the expansion of immunization programs.
- The Pre-Vaccine Era (1980s–Early 2000s): During this period, HBV was a silent epidemic, with childhood prevalence rates as high as 5%. Infants were uniquely vulnerable; statistics showed that approximately 90% of children infected within their first year of life developed chronic, life-long infections, often leading to debilitating liver damage or cancer later in life.
- The Scaling Phase (2000–2019): Global health initiatives, bolstered significantly by the support of Gavi, the Vaccine Alliance, turned the tide. Between 2000 and 2019, the global coverage for the three-dose hepatitis B vaccine series rose from a meager 30% to an impressive 85%.
- The 2020 Milestone: The WHO set a target to reduce HBV prevalence in children under five to below 1% by 2020. With the release of 2019 data confirming that the world has successfully crossed this threshold, the global health community celebrates a major success in public health prevention.
Supporting Data: Successes and Persistent Gaps
While the global average of 85% coverage for the three-dose vaccine is a triumph, the data reveals a more complex narrative of inequality, particularly regarding the "birth dose."
The Critical Birth Dose Disparity
The WHO emphasizes that the first dose of the HBV vaccine, administered within 24 hours of birth, is the most effective tool for preventing mother-to-child transmission.
- Global Average: Only 43% of newborns receive this timely birth dose.
- Regional Inequity: The statistics are starkly uneven. In the WHO Eastern Mediterranean Region, coverage sits at 34%, while in the WHO African Region, the figure is a staggering 6%.
This data underscores a critical gap: the inability to reach newborns in the most high-risk regions. Without the birth dose, the window of opportunity to prevent transmission from an infected mother to her infant closes rapidly.
The Burden of Disease
Despite the success in children, hepatitis B remains a massive global burden. More than 250 million people currently live with chronic HBV, and the virus claims nearly 900,000 lives annually. Hepatitis B and C combined represent the most common cause of viral hepatitis-related deaths, accounting for 1.3 million fatalities every year.
Official Responses and Strategic Pillars
The WHO’s response to these figures is twofold: celebrating the milestone while issuing urgent calls for systemic changes in maternal and neonatal care.
Leadership Perspectives
Dr. Tedros Adhanom Ghebreyesus, Director-General of the WHO, underscored the moral imperative of the mission: "No infant should grow up only to die of hepatitis B because they were not vaccinated. Today’s milestone means that we have dramatically reduced the number of cases of liver damage and liver cancer in future generations."
Dr. Meg Doherty, Director of Global HIV, Hepatitis and STI Programmes, highlighted the strategic necessity of targeting the perinatal period. "Expanding access to a timely birth dose of the hepatitis B vaccine is the cornerstone of efforts to prevent mother-to-child transmission of HBV," she stated.
The "Triple Elimination" Strategy
The WHO is currently promoting a "triple elimination" initiative, which focuses on simultaneously eliminating the mother-to-child transmission of three distinct but interconnected infections: HIV, syphilis, and hepatitis B. By integrating the testing of pregnant women for these three conditions as a routine, comprehensive service, countries can drastically reduce vertical transmission rates.
To support this, the WHO has issued new recommendations favoring the use of antiviral prophylaxis for pregnant women, providing an additional layer of protection that works alongside childhood vaccination.
Implications: The Shadow of COVID-19
Perhaps the most alarming aspect of the current report is the warning regarding the impact of the COVID-19 pandemic on future progress. Scientific modeling conducted by Imperial College London, in collaboration with the WHO, suggests that even a temporary disruption in vaccination programs could undo years of hard-won progress.
Modeling the Worst-Case Scenario
The study highlights that if the pandemic leads to significant disruptions—defined as a 60% decline in the birth dose and a 20% decline in childhood immunization over one year—the long-term consequences would be catastrophic.
The projections suggest that such a disruption, combined with a slow recovery in the post-pandemic period, could lead to:
- 5.3 million additional chronic HBV infections among children born between 2020 and 2030.
- 1 million additional HBV-related deaths among those children as they reach adulthood.
These figures illustrate that the fight against hepatitis is not a static one. The "missed opportunities" to vaccinate newborns today will have life-altering repercussions for the next generation. The pandemic has effectively pushed health systems to their breaking point, and the redirection of resources away from routine immunization represents a significant, long-term threat to global health security.
Towards a Hepatitis-Free Future
The theme of World Hepatitis Day—"Hepatitis-free future"—is both an aspiration and a call to action. Achieving this vision requires a shift from passive monitoring to active, aggressive intervention.
Recommendations for Member States
To bridge the gaps identified in the report, the WHO recommends:
- Intensifying Testing: Implementing routine screening for all pregnant women, ensuring those who test positive receive appropriate antiviral treatment.
- Prioritizing the Birth Dose: Countries, particularly in sub-Saharan Africa, must prioritize the introduction and scale-up of the birth dose as a fundamental part of their neonatal health strategy.
- Maintaining Momentum: Despite the pressures of the pandemic, governments must classify immunization services as essential, ensuring that supply chains and cold-chain infrastructure for vaccines remain robust.
A Concluding Reflection
The reduction of chronic HBV in children under five to below 1% is a testament to what global cooperation, driven by science and supported by entities like Gavi, can achieve. However, this success is not an endpoint. It is a baseline from which the world must build.
The virus remains a formidable adversary, resilient and capable of exploiting any cracks in the global public health armor. As the international community navigates the complexities of a post-pandemic world, the focus must remain steadfast on the most vulnerable. Every infant who misses a timely birth dose represents a potential future death that could have been prevented with a few dollars and a single, well-timed injection. The path forward is clear: the tools to eradicate hepatitis B exist; what remains to be seen is if the political and financial will to deploy them can withstand the current global crises.
